A long-surviving thanatophoric dysplasia type I patient to age of 6 years is presented.
Results and Conclusions
Molecular studies revealed a heterozygous point mutation, S249C in the fibroblast growth factor receptor 3 gene. Most of the clinical course was similar to previous reports, including hearing loss and acanthosis nigricans. Abnormal urinary excretion of dicarboxylic acids and 3-hydroxydicarboxylic acids was observed. We hypothesize that this was a consequence of the FGFR3 mutation.
BakerK.M., OlsonD.S., HardingC.O., PauliR.M.. Long-term survival in typical thanatophoric dysplasia type 1.Am J Med Genet.1997; 70: 427–436.
2.
BallingerS.W., ShoffnerJ.M., HedayaE.V., TrounceI., PolakM.A., KoontzD.A., WallaceD.C.. Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion.Nat Genet.1992; 1: 11–15.
3.
CameraG., MastroiacovoP.. Birth prevalence of skeletal dysplasias in the Italian multicentric monitoring system for birth defects.Prog Clin Biol Res.1982; 104: 441–449.
4.
CollippP.J., SharmaR.K., ThomasJ., MaddaiahV.T., ChenS.Y.. Abnormal glucose tolerance in children with achondroplasia.Am J Dis Child.1972; 124: 682–685.
DowningM., RoseP., BennettM.J., ManningN.J., PollittR.J.. Generalised dicarboxylic aciduria: a common finding in neonates.J Inher Metab Dis.1989; 12(suppl 2): 321–324.
7.
GreterJ., LindstedtS., SeemanH., SteenG.. 3-hydroxydecanedioic acid and related homologues: urinary metabolites in ketoacidosis.Clin Chem.1980; 26: 261–265.
8.
HallJ.G., DorstJ.P., TaybiH., ScottC.I., LangerLOJr., McKusikV.A.. Two probable cases of homozygosity for the achondroplasia gene.Birth Defects Orig Artic Ser.1969; 5: 24–34.
9.
HarrisR., PattonJ.T.. Achondroplasia and thanatophoric dwarfism in the newborn.Clin Genet.1971; 2: 61–72.
10.
KatsumataN., KunoT., MiyazakiS., MikamiS., Nagashima-MiyokawaA., NimuraA., HorikawaR., TanakaT.. G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.Endocr J.1998; 45(suppl): S171–S174.
11.
KelleyR.I., SladkyJ.T.. Dicarboxylic aciduria in an infant with spinal muscular atrophy.Ann Neurol.1986; 20: 734–736.
12.
KunoT., FujitaI., MiyazakiS., KatsumataN.. Markers for bone metabolism in a long-lived case of thanatophoric dysplasia.Endocr J.2000; 47(suppl): S141–S144.
13.
LangerLOJr., YangS.S., HallJ.G., SommerA., KottamasuS.R., GolabiM., KrassikoffN.. Thanatophoric dysplasia and cloverleaf skull.Am J Med Genet.1987; (suppl 3): 167–179.
14.
LiC., ChenL., IwataT., KitagawaM., FuX.Y., DengC.X.. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STAT's and ink4 cell cycle inhibitors.Hum Mol Genet.1999; 8: 35–44.
15.
MacDonaldI.M., HunterA.G., MacLeodP.M., MacMurrayS.B.. Growth and development in thanatophoric dysplasia.Am J Med Genet.1989; 33: 508–512.
16.
MacklerB., ShepardT.H.. Human achondroplasia: defective mitochondrial oxidative energy metabolism may produce the pathophysiology.Teratology.1989; 40: 571–582.
17.
MaroteauxP., LamyM., RobertJ.M.. Le naninme thanatophore.Presse Med.1967; 75: 2519–2524.
18.
NaskiM.C., WangQ., XuJ., OrnitzD.M.. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.Nat Genet.1996; 13: 233–237.
19.
NguyenH.B., EstacionM., GargusJ.J.. Mutations causing achondroplasia and thanatophoric dysplasia alter bFGF-induced calcium signals in human diploid fibroblasts.Hum Mol Genet.1997; 6: 681–688.
20.
OrioliI.M., CastillaE.E., Barbosa-NetoJ.G.. The birth prevalence rates for the skeletal dysplasias.J Med Genet.1986; 23: 328–332.
21.
RiudorE., RibesA., BoronatM., SabadoC., DominguezC., BallabrigaA.. New case of C6-C14 dicarboxylic aciduria with favourable evolution.J Inher Metab Dis.1986; 9(suppl 2): 267–269.
22.
StensvoldK., EkJ., HovlandA.R.. An infant with thanatophoric dwarfism surviving 169 days.Clin Genet.1986; 29: 157–159.
23.
TavorminaP.L., ShiangR., ThompsonL.M., ZhuY.Z., WilkinD.J., LachmanR.S., WilcoxW.R., RimoinD.L., CohnD.H., WasmuthJ.J.. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.Nat Genet.1995; 9: 321–328.
24.
TonokiH.. A boy with thanatophoric dysplasia surviving 212 days.Clin Genet.1987; 32: 415–416.
25.
WilcoxW.R., TavorminaP.L., KrakowD., KitohH., LachmanR.S., WasmuthJ.J., ThompsonL.M., RimoinD.L.. Molecular, radiologic and histopathologic correlations in thanatophoric dysplasia.Am J Med Genet.1998; 78: 274–281.
26.
YangS.S., HeidelbergerK.P., BroughA.J., CorbettD.P., BernsteinJ.. Lethal shortlimbed chondrodysplasia in early infancy.Perspect Pediatr Pathol.1976; 3: 1–40.
